(ISSN 2577-5820)
OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
The journal publishes all types of articles in English. There is no restriction on the length of the papers. We encourage authors to be concise but present their results in as much detail as necessary, as reviewers are expected to emphasize scientific rigor and reproducibility.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)
Special Issue
Progress of Biomarkers in Transplantation
Submission Deadline: July 15, 2025 (Open) Submit Now
Guest Editor
Zoya Kuzmina, MD, PhD
Medical advisor, Austrian Healthcare Center, Vienna, Austria
Research Interests: Biomarker; allo-HSCT; cGVHD; B cells
About This Topic
Research Impact on Progress of Biomarkers in Transplantation:
1. Early Detection of cGVHD: Biomarker discovery facilitates the early identification of patients at risk of developing chronic graft-versus-host disease (cGVHD) after allo-HSCT, enabling timely intervention and reducing disease severity.
2. Personalized Medicine: Biomarkers help in tailoring individualized treatment plans, allowing physicians to adjust immunosuppressive therapy based on the patient's immune profile, improving therapeutic efficacy while minimizing side effects.
3. Prediction of Treatment Response: Biomarkers can serve as predictive tools for how patients will respond to different therapies, including extracorporeal photopheresis (ECP), optimizing treatment strategies and avoiding unnecessary or ineffective therapies.
4. Monitoring Disease Progression: The use of biomarkers in monitoring cGVHD progression allows for real-time assessment of disease activity, making it easier to detect relapses or changes in disease severity, leading to quicker therapeutic adjustments.
5. ECP Response Markers: Biomarkers that can identify patients who are most likely to benefit from ECP therapy can help improve outcomes by ensuring that ECP is used more effectively in those patients.
6. Reduction of Transplant-Related Mortality: By using biomarkers to stratify patients according to their risk of developing cGVHD or other transplant-related complications, clinicians can reduce transplant-related mortality by personalizing post-transplant care.
7. Cost-Effective Healthcare: Implementing biomarker-guided treatment strategies can reduce healthcare costs by minimizing hospitalizations, unnecessary treatments, and by ensuring more targeted, effective care.
8. Immunomodulation Insights: Biomarker research advances understanding of immune dysregulation in cGVHD, guiding the development of novel immunomodulatory therapies, potentially leading to new drug discovery and better treatment options.
9. Improved Quality of Life: Early detection and personalized management of cGVHD using biomarkers can prevent severe complications, improving the quality of life for patients after allo-HSCT.
10. Advancing Research in Transplantation/Regenerative Medicine: Progress in biomarker discovery strengthens the field of transplantation medicine by providing new insights into immune responses, helping to refine protocols, and contributing to ongoing research in post-transplant care, particulary cGVHD, and immunotherapy.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
- Journal Metrics
-
2023 
CiteScore SJR SNIP 0.6 0.179 0.17 - Newsletter
Vidhi is a Clinical yoga therapist; mentor for yoga therapy training in Krishnamacharya tradition. She holds a MSc in Public health from Kings College London.
Mirela Olympia Fagarasan Palmer
Luigi Fontana, MD, PhD.jpg)
Zhong-Ting (Justin) is a PhD student from Nanyang Technological University (Singapore). He holds BSc in Applied Chemistry and MSc in Environmental Engineering. He was a R&D researcher of NanoMaterials Technology Pte Ltd in Singapore (2006-2012). His current research interests are functional nanomaterials synthesis & design, and their application into environmental/chemical engineering. He has published near 60 SCI papers in Applied Catalysis B, Chemical Engineering Journal and so on with H-Index 23. He also serviced as reviewers over 40 Journals such as Appl. Catal. B, Water Research, Chem. Eng. J, ACS Applied Materials & Interface, etc. He was honored such as “The Bsic Research Achievment 1st Award of CIESC”, “The ZJUT Fund Breeding Distinguished Young Scholars” etc.
Rolf Teschke studied Medicine in Munich and Marburg, where he finished his MD thesis before starting a residency at the Department of Pathology, University of Marburg. Subsequently and with a fellowship of the Deutsche Forschungsgmeinschaft, he worked at the Bronx VA Hospital/Mount Sinai Hospital in New York during 1972–1975 together with Professor Charles S. Lieber and successfully isolated MEOS and expanded its characterization. Back in Germany, he was at the Heinrich-Heine University in Düsseldorf with a focus on alcoholic liver disease, biochemical drug studies, and clinical intoxications by halogenated aliphatic hydrocarbons, where he became a Professor of Medicine. In 1987, he was offered a chief position and appointed as Director of the Medical Department II, City Hospital Hanau, Teaching Hospital of the Johann Wolfgang Goethe University Frankfurt/Main. His clinical and research interests are on liver injury by drugs and herbs including causality assessment by RUCAM in close association with Dr. Gaby Danan in Paris. A perfect cooperation exists also with Professor Tran Dang Xuan of the University of Hiroshima, Japan. Finally, he is the author of more than 275 publications including books and book chapters, and he is editor in chief of scientific journals and member of editorial boards.